Suchergebnisse - "Reich, Heather"

PubPharm (230)

1

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy : A Randomized Controlled Trial

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2024

von Barratt, J. | Liew, A. | Yeo, S. | +112

2

Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2024

von Junek, M. | Merkel, P. | Vilayur, E. | +105

3

Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases : designing the right trial for the right patient, today

enthalten in: Kidney international | 2024

von Trachtman, H. | Desmond, H. | Williams, A. | +117

4

Pediatric contributions and lessons learned from the NEPTUNE cohort study

enthalten in: Pediatric nephrology (Berlin, Germany) | 2024

von Modi, Z. | Zhai, Y. | Yee, J. | +109

5

PROTECTing the kidneys in IgA nephropathy

enthalten in: Lancet (London, England) | 2023

von Reich, H. | Barbour, S.

CommentOn: Lancet. 2023 Dec 2;402(10417):2077-2090. - PMID 37931634

6

Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2023

von Peters, B. | Beige, J. | Siwy, J. | +38

7

Focal Segmental Glomerulosclerosis : Assessing the Risk of Relapse

enthalten in: Kidney international reports | 2023

von Troyanov, S. | Jauhal, A. | Reich, H. | +103

8

Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2023

von Barbour, S. | Fervenza, F. | Induruwage, D. | +85

9

Prophylactic Anticoagulation in Nephrotic Syndrome

enthalten in: Kidney360 | 2023

von Gerstein, J. | Battu, K. | Reich, H.

10

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd) : 2-year results from a randomised phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Lafayette, R. | Kristensen, J. | Stone, A. | +10

CommentIn: Lancet. 2023 Sep 9;402(10405):827-829. - PMID 37591290

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]